Intra-articular injection of Erastin induces OA pathological progression as an experimental model

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Developing optimal osteoarthritis (OA) models is critical for therapeutic advancement. While ferroptosis is linked to OA pathogenesis, validated models for studying ferroptosis in OA remain scarce. Methods: In vitro : Mouse/C28I2/human chondrocytes were treated with 10 μM Erastin to assess ferroptosis, inflammation, extracellular matrix degradation, senescence, and antioxidant responses. OA patient and neonatal mouse cartilage explants were cultured ± Erastin (48 h) for Safranin O/IHC analysis. In vivo : 72 C57BL/6J mice (8-week-old) were divided into: (1) Destabilized medial meniscus (DMM) surgery group (Sham: contralateral knee); (2) 1 mg/kg Erastin intra-articular injection; (3) 10 mg/kg Erastin injection. Tissues were collected at 4/8/12 weeks for micro-CT and histology analysis (n=8/group/timepoint). Results: Erastin triggered ferroptosis, senescence, inflammation, and extracellular matrix degradation in mouse/C28I2/human chondrocytes, alongside NRF2 pathway activation and suppressed extracellular matrix synthesis. In cartilage explants (mice/OA patients), Erastin reduced COL2A1 and elevated MMP13 (IHC). In vivo, OARSI scores (Safranin O) and synovitis scores (H&E) increased significantly in DMM and Erastin (1/10 mg/kg) groups vs. Sham. IHC confirmed GPX4/COL2A1 downregulation and MMP13 upregulation in treated groups. Conclusions: A single intra-articular Erastin injection induces chondrocyte degeneration and cartilage damage mimicking human OA, offering a stable, simplified model compared to surgically complex DMM. This approach directly targets ferroptosis pathways, enabling precise mechanistic studies and streamlined preclinical testing of anti-ferroptosis therapies.

Article activity feed